Connection
Jenna Burton to Combined Modality Therapy
This is a "connection" page, showing publications Jenna Burton has written about Combined Modality Therapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.078 |
|
|
|
-
Rebhun RB, Cruz SM, York D, Mazcko CN, Razmara AM, Patkar S, Judge SJ, Sholevar CJ, Shah RK, Zamora AE, Al-Nadaf S, Vail DM, Fan TM, Burton JH, Luker ME, Skorupski KA, Lejeune AT, Woolard K, Stewart SL, Sparger EE, Young J, Cohen-Davidyan T, Huang E, Beck JA, Murphy WJ, Kent MS, Culp WTN, LeBlanc AK, Canter RJ. Phase 2 trial (NCI-COTC030) of adjuvant inhaled recombinant human IL-15 combined with amputation and adjuvant chemotherapy in dogs with appendicular osteosarcoma. Front Immunol. 2025; 16:1672790.
Score: 0.045
-
LeBlanc AK, Mazcko CN, Cherukuri A, Berger EP, Kisseberth WC, Brown ME, Lana SE, Weishaar K, Flesner BK, Bryan JN, Vail DM, Burton JH, Willcox JL, Mutsaers AJ, Woods JP, Northrup NC, Saba C, Curran KM, Leeper H, Wilson-Robles H, Wustefeld-Janssens BG, Lindley S, Smith AN, Dervisis N, Klahn S, Higginbotham ML, Wouda RM, Krick E, Mahoney JA, London CA, Barber LG, Balkman CE, McCleary-Wheeler AL, Suter SE, Martin O, Borgatti A, Burgess K, Childress MO, Fidel JL, Allstadt SD, Gustafson DL, Selmic LE, Khanna C, Fan TM. Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs. Clin Cancer Res. 2021 06 01; 27(11):3005-3016.
Score: 0.033
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|